Overview

A Study to Evaluate Long-term Safety of Ecopipam Tablets in Children, Adolescents and Adults With Tourette's Disorder

Status:
ACTIVE_NOT_RECRUITING

Trial end date:
2027-03-01

Target enrollment:

Participant gender:

Summary

The primary objective of this study is to evaluate the long-term safety and tolerability of ecopipam tablets in children (greater than or equal to \[\>=\] 6 and less than \[\<\] 12 years of age), adolescents (\>=12 and \<18 years of age), and adults (\>=18 years of age) with Tourette's Syndrome (TS).

Phase:

PHASE3

Details

Lead Sponsor:

Emalex Biosciences Inc.

Treatments:

ecopipam